Abstract:
PURPOSE OF REVIEW:Social media has dramatically changed the access and exchange of information in healthcare and beyond. A variety of platforms and resources exist allowing blood and marrow transplant providers, researchers, and patients to interact. We review the adoption of social media by the transplantation community. RECENT FINDINGS:Social media allows on-demand access to the latest developments at national and international meetings, newly published research articles, facilitates networking with colleagues, participation in advocacy, and promoting available clinical trials. For the modern transplantation provider, the scope and ease of access to these benefits are unparalleled. Social media serves as a gateway to access relevant resources and communities for both providers and patients as it pertains to transplantation. We demonstrate the utilization and applications of social media among stem cell transplantation providers, patients, and other affiliated stakeholders. A variety of resources and communities have enhanced and increased the opportunities for engagement.
journal_name
Curr Hematol Malig Repjournal_title
Current hematologic malignancy reportsauthors
Patel SS,Majhail NSdoi
10.1007/s11899-018-0487-1subject
Has Abstractpub_date
2018-12-01 00:00:00pages
576-580issue
6eissn
1558-8211issn
1558-822Xpii
10.1007/s11899-018-0487-1journal_volume
13pub_type
杂志文章,评审abstract::A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-013-0176-z
更新日期:2013-12-01 00:00:00
abstract:PURPOSE OF REVIEW:Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0480-8
更新日期:2018-12-01 00:00:00
abstract::In recent years, the treatment of multiple myeloma has undergone significant changes. The availability of novel agents bortezomib, thalidomide and lenalidomide considerably improved the outcome of patients. The advantages related to the use of novel agents have been shown in various studies in patients eligible and in...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-013-0177-y
更新日期:2013-12-01 00:00:00
abstract:PURPOSE OF REVIEW:In this review article, we will highlight ethical issues faced by hematologists due to a growing constellation of expensive diagnostics and therapeutics in hematology. We outline the important issues surrounding this topic including stakeholders, cost considerations, and various ethical challenges sur...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00599-w
更新日期:2020-10-01 00:00:00
abstract::Acute myeloid leukemia (AML) is a complex clonal disorder. The disease is characterized by chromosomal and molecular abnormalities that propagate and expand the abnormal clone(s). The main goal of therapy is to achieve and ultimately maintain a complete remission. In the younger AML patient (less than 60 years of age)...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-016-0339-9
更新日期:2016-10-01 00:00:00
abstract::Measuring the quality of care for patients with chronic cancers is difficult, especially for heterogeneous malignancies such as the myelodysplastic syndromes (MDS). Recent work suggests that improvements may be needed in the quality of diagnostic, treatment, and end-of-life care for patients with these syndromes. More...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-016-0343-0
更新日期:2016-12-01 00:00:00
abstract::Myeloproliferative neoplasms (MPNs) are stem cell-derived clonal myeloid malignancies characterized by a unique somatic mutational profile since three mutually exclusive mutations (JAK2V617F, MPL, and CALR) sustain the great majority of the cases. However, clinical observation that autoimmune diseases may predispose t...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-014-0227-0
更新日期:2014-12-01 00:00:00
abstract:PURPOSE OF REVIEW:Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematic...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0445-y
更新日期:2018-06-01 00:00:00
abstract::Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). Traditionally accepted indications for allografting adult ALL patients need reevaluation in light of outcomes with paediatric-like intensive regimens. Minimal residual disease status an...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-017-0371-4
更新日期:2017-04-01 00:00:00
abstract::Patients with acute leukemia who undergo hematopoietic stem cell transplantation (HSCT) are susceptible to malnutrition caused by several factors including intensive cytotoxic therapy. This paper discusses the significance of malnutrition in these patients and provides an overview of nutrition therapy by the oral, ent...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-996-0007-6
更新日期:2006-09-01 00:00:00
abstract:PURPOSE OF REVIEW:CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically needed. We review re...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00557-6
更新日期:2020-04-01 00:00:00
abstract::Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include p...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-011-0099-5
更新日期:2011-12-01 00:00:00
abstract::Allogeneic hematopoietic cell transplantation (HCT) has curative potential for patients with myelodysplastic syndromes (MDS), though with considerable nonrelapse mortality and morbidity. The International Prognostic Scoring System, despite its confines, remains a widely used tool guiding treatment decisions in MDS. Th...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-009-0035-0
更新日期:2010-01-01 00:00:00
abstract::BCR-ABL-negative myeloproliferative neoplasms include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Clonal stem cell proliferation and dysregulated JAK/STAT molecular pathways characterize these hematologic malignancies. Symptoms experienced by patients are heterogeneous including excessive ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-014-0239-9
更新日期:2014-12-01 00:00:00
abstract::Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0250-9
更新日期:2015-06-01 00:00:00
abstract:PURPOSE OF REVIEW:Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with long-term use. Fedratinib, momelotinib, and pa...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00596-z
更新日期:2020-12-01 00:00:00
abstract:PURPOSE OF REVIEW:To provide an update on the pathogenesis of enteropathy-associated T cell lymphoma (EATL) and its relationship with refractory celiac disease (RCD), in light of current knowledge of immune, genetic, and environmental factors that promote neoplastic transformation of intraepithelial lymphocytes (IELs)....
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0459-5
更新日期:2018-08-01 00:00:00
abstract::The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by gen...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-013-0184-z
更新日期:2013-12-01 00:00:00
abstract::Progress in the understanding of the biology of chronic lymphocytic leukemia and in the development of new and effective therapies has generated a shift in treatment paradigms within only a few years. Traditional chemotherapy agents such as alkylators or nucleoside analogs are rapidly being replaced by combination reg...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-006-0006-7
更新日期:2006-12-01 00:00:00
abstract:PURPOSE OF REVIEW:This article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma. RECENT FINDINGS:The clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis on the most recently published data regarding the ZUMA-1,...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0482-6
更新日期:2018-12-01 00:00:00
abstract::The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 %...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0273-2
更新日期:2015-09-01 00:00:00
abstract::Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that is curable in at least 80 % of patients. Although patients usually present with painless lymphadenopathy, a variety of systemic and organ-specific syndromes may also exist in relation to HL. These syndromes may develop before, during, or after the...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-012-0131-4
更新日期:2012-09-01 00:00:00
abstract::Advances in chemotherapy administration have made acute lymphoblastic leukemia (ALL) a curable disease; however, most patients will relapse, despite readily attaining a complete remission. Treatment of relapse has shown dismal results with little advances made in the recent decades. Antigenic-directed therapy of ALL c...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-012-0120-7
更新日期:2012-06-01 00:00:00
abstract:PURPOSE OF REVIEW:Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond,...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0477-3
更新日期:2018-12-01 00:00:00
abstract:PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00593-2
更新日期:2020-08-01 00:00:00
abstract::The advent of social media has led to the ability for individuals all over the world to communicate with each other, in real time, about mutual topics of interest in an unprecedented manner. Recently, the use of social media has increased among people interested in healthcare and medical research, particularly in the ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0287-9
更新日期:2015-12-01 00:00:00
abstract::Just as a pawnshop owner who is unable to distinguish a genuine Rolex™ watch from a cheap knockoff courts financial ruin, the physician who fails to discriminate between authentic myelodysplastic syndromes (MDS) and conditions resembling MDS risks misinforming or harming patients. This review summarizes minimal criter...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-012-0140-3
更新日期:2012-12-01 00:00:00
abstract::Acute promyelocytic leukemia (APL) is characterized by coagulopathy, leukopenic presentation and sensitivity to anthracyclines, all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). For the last 25 years, APL has been treated with a combination of ATRA and chemotherapy for induction followed by consolidation and ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-014-0205-6
更新日期:2014-06-01 00:00:00
abstract::Hodgkin's lymphoma (HL) is a relatively rare disease accounting for 15 % of all lymphoma. This disease has developed from an incurable disease to the adult malignancy with the most favorable prognosis. With current therapeutic approaches consisting of polychemo- and small-field radiotherapy, up to 80 % of all patients...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0262-5
更新日期:2015-09-01 00:00:00
abstract::The introduction of imatinib represented a breakthrough in the treatment of chronic myelogenous leukemia (CML). However, about 20% of patients treated in early chronic-phase CML are off therapy after 6 years because of resistance or intolerance, and most patients taking imatinib remain BCR-ABL-positive at the molecula...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章
doi:10.1007/s11899-008-0012-z
更新日期:2008-04-01 00:00:00